<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_TECHNION-ISRAEL_Diseases skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:TECHNION-ISRAEL/Diseases</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><TITLE>navbar</TITLE></P><DIV class="container-fluid" style="margin-top:0px;"><DIV class="row"><DIV class="col-md-12"><NAV class="navbar navbar-inverse navbar-fixed-top " style=" z-index:800; position:fixed; margin:auto; width: 1180px ;"><DIV class="dropdown" style="padding-left: 100px;"><BUTTON class="dropdown-toggle" type="button" data-toggle="dropdown"><A href="https://2017.igem.org/Team:TECHNION-ISRAEL"> project </A></BUTTON><UL class="dropdown-menu" style=" margin: 0px;  left:78px;"><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Description"> description </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Diseases"> Diseases &amp; Epitopes </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Design"><SPAN id="T">T</SPAN>ri-Display </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/delay_mechanism"><SPAN id="T">  T</SPAN>iming </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/kill_switch"><SPAN id="T">T</SPAN>erminate</A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Demonstrate"><SPAN id="T"> T</SPAN>olerance Assay </A></LI></UL></DIV><DIV class="dropdown"><BUTTON class="dropdown-toggle" type="button" data-toggle="dropdown"> wet lab 
							</BUTTON><UL class="dropdown-menu" style="margin: 0px;  left: 2px;"><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/cell_lines"> cell lines </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Results"> results </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/hpc7"> hpc-7 results </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Notebook"> notebook </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Experiments"> protocols </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/InterLab"> interlab </A></LI></UL></DIV><DIV class="dropdown"><BUTTON class="dropdown-toggle" type="button" data-toggle="dropdown"><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Parts"> parts </A></BUTTON><UL class="dropdown-menu" style="margin: 0px;  left: 2px;"><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Parts"> parts </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Basic_Part"> basic part </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Composite_Part"> composite part </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Part_Collection"> part collection </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Improve">	 improvement </A></LI></UL></DIV><DIV class="dropdown"><BUTTON class="dropdown-toggle" type="button" data-toggle="dropdown" style="width: auto"> human practices 
							</BUTTON><UL class="dropdown-menu" style="margin: 0px;  left: 18px; width: 170px;"><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/HP/Silver"> HP silver </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Engagement"> Education &amp; Public Engagement </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/HP/Gold_Integrated"> integrated HP </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/ethics"> ethics </A></LI></UL></DIV><DIV class="dropdown"><BUTTON class="dropdown-toggle" type="button" data-toggle="dropdown"> judging
							</BUTTON><UL class="dropdown-menu" style="margin: 0px;  left: 2px "><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Safety"> safety </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Collaborations"> collaboration </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Achievements"> achievements </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Model"> modelling </A></LI></UL></DIV><DIV class="dropdown" style="padding-right: 100px;"><BUTTON class="dropdown-toggle" type="button" data-toggle="dropdown">team
							</BUTTON><UL class="dropdown-menu" style=" margin: 0px;  left: 2px;"><LI><A href=" https://2017.igem.org/Team:TECHNION-ISRAEL/Team"> members </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Attributions"> attributions </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/gallery"> gallery </A></LI></UL></DIV></NAV></DIV></DIV></DIV><P><TITLE>Modular Tri-Display plasmid</TITLE></P><DIV class="container-fluid"><DIV class="row"><H1> Diseases &amp; Epitopes </H1><DIV class="col-md-offset-2 col-md-8"><P>
			There are hundreds of autoimmune and allergic diseases. They have a tremendous effect on people’s lives, and exact a heavy financial and emotional cost.  In our project, we chose to focus on five specific diseases. We chose these diseases because they are familiar and very different in their pathophysiology, thus demonstrating both the pertinence, and modularity, of our proposed treatment.
			</P><DIV class="row"><DIV class="col-md-12"><DIV id="wrapush"><P class="text">click on the different parts in the image</P></DIV><H3> Epitopes </H3><P>An Epitope is the part of an antigen that is recognized by the immune system, specifically by antibodies, B cells, or T cells. 
Below are the epitopes we used to prevent the diseases we focused on. </P><TABLE class="table table-list-search"><THEAD><TR><TH style="width:25%; vertical-align :middle !important;">Allergies / autoimmune diseases </TH><TH style="width:40%; vertical-align :middle !important;">Epitopes </TH><TH style="width:35%; vertical-align :middle !important;">Amino acids sequences  </TH></TR></THEAD><TBODY><TR><TD rowspan="3" style="vertical-align :middle !important;">Multiple sclerosis </TD><TD>Domain 1 in the MOG - myelin oligodendrocyte protein</TD><TD>GQFRVIGPGHPIRALVGDEAE<SUP id="cite ref-9 " class="reference"><A href="#ref9" original-title="">[9] </A></SUP></TD></TR><TR><TD>Domain 2 in the MOG - myelin oligodendrocyte protein</TD><TD>MEVGMYRSPFSRVVHLYRNGK<SUP id="cite ref-9 " class="reference"><A href="#ref9" original-title="">[9] </A></SUP></TD></TR><TR><TD>Domain 3 in the MOG - myelin oligodendrocyte protein</TD><TD>SYQEEAAVELKVED<SUP id="cite ref-9 " class="reference"><A href="#ref9" original-title="">[9] </A></SUP></TD></TR><TR><TD style="vertical-align :middle !important;">Diabetes type 1</TD><TD>Proinsulin</TD><TD>MALWMRLLPL LALLALWGPD PAAAFVNQHLCGSHLVEALY LVCGERGFFYTPKTRREAED LQVGQVELGG GPGAGSLQPL ALEGSLQKRG IVEQCCTSIC SLYQLENYCN<SUP id="cite ref-10 " class="reference"><A href="#ref10" original-title="">[10] </A></SUP></TD></TR><TR><TD rowspan="3" style="vertical-align :middle !important;">Celiac</TD><TD>Domain 1 in the 33 mer peptide</TD><TD>PFPQPQLPY<SUP id="cite ref-11 " class="reference"><A href="#ref11" original-title="">[11] </A></SUP><SUP id="cite ref-12 " class="reference"><A href="#ref12" original-title="">[12] </A></SUP></TD></TR><TR><TD>Domain 2 in the 33 mer peptide</TD><TD>PQPQLPYPQ<SUP id="cite ref-11 " class="reference"><A href="#ref11" original-title="">[11] </A></SUP><SUP id="cite ref-12 " class="reference"><A href="#ref12" original-title="">[12] </A></SUP></TD></TR><TR><TD>Domain 3 in the 33 mer peptide</TD><TD>PYPQPQLPY<SUP id="cite ref-11 " class="reference"><A href="#ref11" original-title="">[11] </A></SUP><SUP id="cite ref-12 " class="reference"><A href="#ref12" original-title="">[12] </A></SUP></TD></TR><TR><TD rowspan="3" style="vertical-align :middle !important;">Peanut allergy</TD><TD>Overlapping domain 1 between Ara-h2 and Ara-h6 proteins</TD><TD>KRELRN<SUP id="cite ref-13 " class="reference"><A href="#ref13" original-title="">[13] </A></SUP><SUP id="cite ref-14 " class="reference"><A href="#ref14" original-title="">[14] </A></SUP></TD></TR><TR><TD>Overlapping domain 2 between Ara-h2 and Ara-h6 proteins</TD><TD>LQGRQQ<SUP id="cite ref-13 " class="reference"><A href="#ref13" original-title="">[13] </A></SUP><SUP id="cite ref-14 " class="reference"><A href="#ref14" original-title="">[14] </A></SUP></TD></TR><TR><TD>Overlapping domain 3 between Ara-h2 and Ara-h6 proteins</TD><TD>DPYSPS<SUP id="cite ref-13 " class="reference"><A href="#ref13" original-title="">[13] </A></SUP><SUP id="cite ref-14 " class="reference"><A href="#ref14" original-title="">[14] </A></SUP></TD></TR><TR><TD rowspan="3" style="vertical-align :middle !important;">Bee venom allergy</TD><TD>Domain 1 in the phospholipase A2 (PLA) protein</TD><TD>CLHYTVDKSKPK<SUP id="cite ref-15 " class="reference"><A href="#ref15" original-title="">[15] </A></SUP></TD></TR><TR><TD>Domain 2 in the phospholipase A2 (PLA) protein</TD><TD>YFVGKMYFNLID<SUP id="cite ref-15 " class="reference"><A href="#ref15" original-title="">[15] </A></SUP></TD></TR><TR><TD>Domain 3 in the phospholipase A2 (PLA) protein</TD><TD>ESKHGLTNTASHTRLSCD<SUP id="cite ref-15 " class="reference"><A href="#ref15" original-title="">[15] </A></SUP></TD></TR></TBODY></TABLE><DIV class="references"><OL><LI id="ref1">Ewan, Pamela W. &quot;ABC of allergies: venom allergy.&quot; BMJ: <I>British Medical Journal</I> 316.7141 (1998): 1365.‏‏</LI><LI id="ref2">Müller, U., et al. &quot;Increased specificity of diagnostic tests with recombinant major bee venom allergen phospholipase A2.&quot; <I>Clinical &amp; Experimental Allergy</I> 27.8 (1997): 915-920.‏</LI><LI id="ref3">Al-Muhsen, Saleh, Ann E. Clarke, and Rhoda S. Kagan. &quot;Peanut allergy: an overview.&quot;<I> Canadian Medical Association Journal</I> 168.10 (2003): 1279-1285.</LI><LI id="ref4">Mueller, Geoffrey A., Soheila J. Maleki, and Lars C. Pedersen. &quot;The molecular basis of peanut allergy.&quot; <I>Current allergy and asthma reports </I>14.5 (2014): 1-9.‏‏</LI><LI id="ref5">Dilokthornsakul, Piyameth, et al. &quot;Multiple sclerosis prevalence in the United States commercially insured population.&quot;<I> Neurology</I> 86.11 (2016): 1014-1021.‏</LI><LI id="ref6">Fletcher, J. M., et al. &quot;T cells in multiple sclerosis and experimental autoimmune encephalomyelitis.&quot; <I>Clinical &amp; Experimental Immunology</I> 162.1 (2010): 1-11.‏‏</LI><LI id="ref7">Gujral, Naiyana, Hugh J. Freeman, and Alan BR Thomson. &quot;Celiac disease: prevalence, diagnosis, pathogenesis and treatment.&quot;<I>7 World journal of gastroenterology: WJG</I> 18.42 (2012): 6036.‏</LI><LI id="ref8">Reuters, Thomson. “Diabetes cases soar to record 382 million worldwide.” CBCnews, CBC/Radio Canada, 14 Nov. 2013, www.cbc.ca/news/health/diabetes-cases-hit-record-382-million-worldwide-1.2426381.‏</LI><LI id="ref9">Mendel, Itzhack, Nicole Kerlero de Rosbo, and Avraham Ben‐Nun. &quot;A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: Fine specificity and T cell receptor Vβ expression of encephalitogenic T cells.&quot; <I>European journal of immunology</I> 25.7 (1995): 1951-1959.‏</LI><LI id="ref10">Narendran, Parth, Stuart I. Mannering, and Leonard C. Harrison. &quot;Proinsulin—a pathogenic autoantigen in type 1 diabetes.&quot; <I>Autoimmunity reviews</I> 2.4 (2003): 204-210</LI><LI id="ref11">Ozuna, Carmen V., et al. &quot;Diversification of the celiac disease α‐gliadin complex in wheat: a 33‐mer peptide with six overlapping epitopes, evolved following polyploidization.&quot; <I>The Plant Journal </I>82.5 (2015): 794-805</LI><LI id="ref12">Schalk, Kathrin, et al. &quot;Quantitation of the immunodominant 33-mer peptide from α-gliadin in wheat flours by liquid chromatography tandem mass spectrometry.&quot; <I>Scientific Reports</I> 7 (2017): 45092.</LI><LI id="ref13">Mishra, Ankita, Anuja Jain, and Naveen Arora. &quot;Mapping B‐cell epitopes of major and minor peanut allergens and identifying residues contributing to IgE binding.&quot; <I>Journal of the science of food and agriculture</I> 96.2 (2016): 539-547.</LI><LI id="ref14">Otsu, K., R. Guo, and S. C. Dreskin. &quot;Epitope analysis of Ara h 2 and Ara h 6: characteristic patterns of IgE‐binding fingerprints among individuals with similar clinical histories.&quot; <I>Clinical &amp; Experimental Allergy</I> 45.2 (2015): 471-484.</LI><LI id="ref15">Carballido, J. M., et al. &quot;T cell epitope specificity in human allergic andnonallergic subjects to bee venom phospholipase A2.&quot; <I>The Journal of Immunology</I> 150.8 (1993): 3582-3591</LI></OL></DIV></DIV></DIV></DIV></DIV></DIV><TITLE>My First Website</TITLE><DIV class="footer"><DIV class="container-fluid"><DIV class="row"><DIV class="col-md-offset-1 col-md-10"><DIV class="row"><DIV class="col-md-4 nopadding"><DIV class="location"><P style="text-indent:inherit; margin-top: 30px; padding-bottom:15px;color:  #ffffff; 	font-family:  'Quicksand', sans-serif; 	font-size: 14px; 	line-height:25px; 	text-align: unset;">
											
							Department of Biotechnology &amp; Food Engineering
							
							
							Technion – Israel Institute of Technology
							
							
							Haifa 32000, Israel
							</P></DIV></DIV><DIV class="col-md-offset-3 col-md-3"><DIV class="contact" style="margin-top: 20px;"><UL><P style=" text-indent:inherit; margin-top: 5px; color:  #ffffff; font-family: 'Quicksand', sans-serif;	font-size: 14px;">
									igem.technion.2017@gmail.com
									</P></UL></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>